Project ID：BP-20240718-OR-77
Product Brief Summary
- Product Name: A safer and more effective small-molecule regulator of miR-124 for IBD treatment
- Modality: Small Molecule
- Target: miR-124
- Therapeutic Area: IBD
- Current Stage: pre-clinical
- Rights Available: China/Global Right
- Collaboration Mode: License out / co-development
More highlights
- Compared with ABX464, the candidate showed more potent in vitro activity for up-regulating miR-124
- Enhanced in vitro activity and superior in vivo activity were observed
- Better oral absorption profiles and more desirable ADMET properties
- No obvious toxicity was found in animal anatomy and gross examination
Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
发布者：qi.yang，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 